Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)
Conditions
Interventions
PTC857
Placebo
Locations
55
United States
UC Irvine Health ALS and Neuromuscular Center
Orange, California, United States
Forbes Norris MDA/ALS Research Center at California Pacific Medical Center
San Francisco, California, United States
Holy Cross Hospital, Phil Smith Neuroscience Institute
Fort Lauderdale, Florida, United States
University of South Florida - Carol and Frank Morsani Center for Advanced Healthcare
Tampa, Florida, United States
Augusta University
Augusta, Georgia, United States
University of Kansas Medical Center (KUMC) - Landon Center on Aging
Kansas City, Kansas, United States
Start Date
May 15, 2022
Primary Completion Date
September 26, 2024
Completion Date
January 30, 2025
Last Updated
August 1, 2025
NCT07322003
NCT07414212
NCT05104710
NCT03233646
NCT04715399
NCT07357428
Lead Sponsor
PTC Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions